Our Parkinson's Place: Voyager’s AADC Gene Therapy Shows Promise as Maintenance Therapy for Parkinson’s

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Thursday, October 26, 2017

Voyager’s AADC Gene Therapy Shows Promise as Maintenance Therapy for Parkinson’s

OCTOBER 26, 2017 BY CATARINA SILVA

Voyager Therapeutics’ new clinical data on VY-AADC01 as a maintenance therapy for advanced Parkinson’s disease shows improvement in patients’ motor function after just one dose, and with meaningfully lower doses of oral levodopa.

The company presented ongoing Phase 1b trial (NCT01973543) results at the Oct. 17-20 Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin, in a talk titled “Intraputaminal AADC gene therapy for advanced Parkinson’s disease: Interim Results of a Phase 1b Trial.”

Adendo-associated viruses (AAV) are small viruses that can infect humans and primates without causing disease. AAV gene therapy enables the delivery of specific genetic sequences.

“A core competency of Voyager’s gene therapy platform is vector optimization and a critical component of this is optimizing and choosing the capsid, or outer shell of the gene therapy vector,” Dr. Dinah Sah, Voyager’s chief scientific officer, said in a press release. The outer shell of the AAV is an essential component, and must be customized to ensure correct gene delivery.

In normal conditions, levodopa is converted to dopamine by 1-amino acid decarboxylase (AADC). This enzyme acts on nerve terminals between the substantia nigra and striatum. In Parkinson’s, a severe loss of these nerve terminals is associated with a decrease in AADC activity. As a result, patients’ motor symptoms worsen.

Voyager’s VY-AADC01 was designed to deliver the AADC gene, which codes for the AADC enzyme, directly into neurons of Parkinson’s patients’ putamen. The putamen is part of the striatum that has dopamine receptors. This allows the putamen neurons to restore the conversion of levodopa to dopamine.

Motor function was then measured by patient-reported diaries, Parkinson’s disease rating scales, and activities of daily living.

Results show that after a single intravenous administration of VY-AADC01, motor function improved in a durable dose- and time-dependent way. Interestingly, this also happened with lower doses of oral levodopa.

Despite the promising results, Voyager will continue to monitor this trials’ patients. In addition, the pharmaceutical company already plans a pivotal Phase 2/3 trial, which will likely start enrollment in the first half of 2018.

https://parkinsonsnewstoday.com/2017/10/26/parkinsons-aadc-gene-therapy-shows-promise-as-maintenance-treatment-voyager-says/